Last reviewed · How we verify

GSK 573719 +GW642444 125/25 — Competitive Intelligence Brief

GSK 573719 +GW642444 125/25 (GSK 573719 +GW642444 125/25) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA). Area: Respiratory / Pulmonology.

phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; Beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GSK 573719 +GW642444 125/25 (GSK 573719 +GW642444 125/25) — GlaxoSmithKline. This combination inhaler delivers a long-acting muscarinic antagonist (umeclidinium) and a long-acting beta-2 agonist (vilanterol) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK 573719 +GW642444 125/25 TARGET GSK 573719 +GW642444 125/25 GlaxoSmithKline phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; Beta-2 adrenergic receptor
Tiotropium & olodaterol Tiotropium & olodaterol University of Dundee marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
UMEC/VI UMEC/VI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
GSK573719/VI 62.5/25 GSK573719/VI 62.5/25 GlaxoSmithKline phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
Glycopyrronium/Formoterol Fumarate Glycopyrronium/Formoterol Fumarate AstraZeneca phase 3 LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) Muscarinic M3 receptor; Beta-2 adrenergic receptor
Umeclidinium/Vilanterol 62.5/25 mcgs Umeclidinium/Vilanterol 62.5/25 mcgs National Institute of Respiratory Diseases, Mexico marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Aclidinium bromide & formoterol fumarate Aclidinium bromide & formoterol fumarate University of Dundee marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class)

  1. GlaxoSmithKline · 5 drugs in this class
  2. University of Dundee · 2 drugs in this class
  3. National Institute of Respiratory Diseases, Mexico · 1 drug in this class
  4. University of Tennessee Graduate School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK 573719 +GW642444 125/25 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-573719-gw642444-125-25. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: